About Geron
Geron is a publicly listed company based in Menlo Park (United States) founded in 1992. Telomerase inhibitors are developed for haematological myeloid malignancies treatment. It operates on a HealthTech model. The company has 229 employees. Its chief executive, as recorded, is John Scarlett. Its website geron.com draws about 11 thousand monthly visits. Geron offers products and services including Blood Cancer Medicine and Telomerase Inhibition Therapy. Its focus areas include Biotechnology and Cancer Therapeutics. Similar companies include C4 Therapeutics, Erasca and MiRagen; 3 of its 3 listed similar companies have raised funding.
Company details
Geron is engaged in the research and development of innovative medicines targeting myeloid hematologic malignancies. The company is dedicated to changing the course of blood cancers through pioneering science. Solutions are developed to extend and enhance patients lives, with a primary focus on telomerase inhibition therapies and approved medicines in the United States. The healthcare sector, specifically biotechnology for cancer therapeutics, is the core area of operation for Geron.
- Annual Revenue$183.88 M (USD)138.83as on Dec 31, 2025
- Net Profit-$83.5 M (USD)52.17as on Dec 31, 2025
- EBITDA-$50.35 M (USD)70.81as on Dec 31, 2025
- Latest Funding Round$4M (USD), Post-IPO
Mar 1998
- Employee Count229
Products & Services of Geron
Geron offers a comprehensive portfolio of products and services, including Blood Cancer Medicine and Telomerase Inhibition Therapy.
Medicine for blood cancer treatment is provided by Geron.
Therapy targeting telomerase for cancer treatment is developed.
Funding Insights of Geron
- Total Rounds 1
- Last Round Post-IPO — $4M
- First Round $4M
(Mar 1998)
All 1 funding rounds of Geron with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 1998 | $4M | Post-IPO | – | – | – |
People of Geron
65 people are tracked at Geron (31 in leadership, 7 in board & advisors, 27 in team); the tracked headcount is 229.
| Name | Role | Group |
|---|---|---|
John Scarlett | Chairman & CEO | Leadership |
Kellie Winemiller Rn Bsn | Field Reimbursement And Access Director | Leadership |
Melissa A. Kelly Behrs | EVP, Business Operations & Chief Alliance Officer | Leadership |
Shannon Odam | VP, Human Resources | Leadership |
Ying Wan | Senior Vice President, Vice President, Head Of Biometrics And Data Management | Leadership |
Jimmy Evans | National Account Director, Payers | Leadership |
Nora E. B. | Head Of Quality Assurance & Quality Systems | Leadership |
Libo Sun | Executive Director, Biostatistics | Leadership |
Eric Mueller | Sr. Director Of Process Development And Manufacturing | Leadership |
Sarfraz Haroon | Associate Director, Clinical Data Management | Leadership |
Ben Thorp | Head Of Clinical Data Management | Leadership |
Travis Humphreys | Director, Clinical Quality Assurance | Leadership |
Surya Wiryo | Sr Director Information Management & Enterprise Platform Services | Leadership |
Tim Tickner | Senior Director, Supply Chain Management | Leadership |
Rachel Williams | Vice President Human Resources | Leadership |
Jennifer Allen | Director, Talent Acquisition | Leadership |
Patrick Murphy | Vice President Of Manufacturing | Leadership |
Jeannie Wall | Associate Director, Clinical Quality Assurance | Leadership |
Joe Denton | Senior Director Quality | Leadership |
Shannon Maryman | Director, Reimbursement & Regional Accounts | Leadership |
45 more people are available in the full profile.
Complete people profiles for Geron
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Geron
Geron is a publicly listed company on the NASDAQ with ticker symbol GERN in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date30 Jun 1996
- Listed onNASDAQ: GERN
- Listed entityGeron Corporation
- Exchange sectorHealth technology
- ISINUS3741631036
- Share price$1.20 (-1.64% on the day) · 2026-10-13
- Market capitalisation$771.0M
- EPS (diluted, trailing year)$-0.10
- Volume (last session)7,578,160
Financials of Geron
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $183.9M | -$83.5M | -$50.4M |
| 2024 | $77.0M | -$174.6M | -$172.5M |
| 2023 | $237,000 | -$184.1M | -$192.9M |
| 2022 | $596,000 | -$141.9M | -$137.7M |
| 2021 | $1.4M | -$116.1M | -$113.2M |
Detailed financial statements for Geron
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Geron
3 dated milestones of Geron across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Geron is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $4.0M.
Similar companies to Geron
Geron has 3 listed similar companies in our database, 3 of them funded. They include C4 Therapeutics, Erasca and MiRagen.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. | |
| erasca.com | 2018 | San Diego, United States | $300M | 120 | Small molecule therapeutics for cancer treatment are developed. | |
| miragen.com | 2007 | Boulder, United States | $111.29M | 92 | MicroRNA-based therapeutics are developed for treating multiple diseases. |
Detailed similar companies of Geron
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Geron
The website of Geron (geron.com) receives about 11K visits a month.
- Monthly visits11K
▼ 12.2% vs previous month
Websites whose visitors overlap most with Geron. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
biotimeinc.com | biotimeinc.com | 100% | – | ||
| gilead.com | 88% | 576.5K | #103,109 | View details | |
| cepheid.com | 75% | 117.9K | #496,659 | View details | |
invernessmedical.com | invernessmedical.com | 75% | – | ||
| viropharma.com | 75% | View details | |||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 22 similar websites and full traffic analytics for Geron
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 22 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Oncology
3 companies that operate in the same segment as Geron (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Geron
Complete news archive for Geron
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Geron
Geron was founded in 1992 and raised its 1st funding round 6 years after it was founded.
Geron is headquartered in Menlo Park, United States. It is registered at Menlo Park, California, United States.
John Scarlett is the CEO of Geron, as recorded in our data.
Geron has 229 employees.
Annual revenue of Geron is $183.88M as on Dec 31, 2025.
Geron is engaged in the research and development of innovative medicines targeting myeloid hematologic malignancies. The company is dedicated to changing the course of blood cancers through pioneering science. Solutions are developed to extend and enhance patients lives, with a primary focus on telomerase inhibition therapies and approved medicines in the United States. The healthcare sector, specifically biotechnology for cancer therapeutics, is the core area of operation for Geron.
Geron's top competitors include C4 Therapeutics, Erasca and MiRagen.
Geron offers Blood Cancer Medicine and Telomerase Inhibition Therapy.
Yes, Geron is publicly traded on NASDAQ under the ticker symbol GERN.
Geron operates through Geron.